MAYO CLINIC LABORATORIES

NEW TEST

Notification Date: July 15, 2022
Effective Date: August 16, 2022

Phospholipase A2 Receptor, Immunofluorescence, Serum

Test ID: PLA2I

Useful for:

Distinguishing primary from secondary membranous nephropathy in patients with low levels of anti-phospholipase A2 receptor (PLA2R) antibodies

Screening for anti-PLA2R antibodies

Monitoring patients with membranous nephropathy at very low antibody titers

Method:

Indirect Immunofluorescence Assay (IFA)

Reference Values:

Negative

Specimen Requirements:

Preferred:	Serum gel
Acceptable:	Red top
Specimen Volume:	1 mL
Collection Instructions:	Centrifuge and aliquot serum into plastic vial within 2 hours of collection
Minimum Volume:	0.5 mL

Specimen Stability Information:

Specimen Type	Temperature	Time
Serum	Refrigerated (preferred)	14 days
	Ambient	8 hours
	Frozen	14 days

Cautions:
This test should not be used as a stand-alone test but an adjunct to other clinical information. A diagnosis of primary or secondary membranous nephropathy (MN) should not be made on a single test result. The clinical symptoms, results on physical examination, and laboratory tests (eg, serological tests), when appropriate, should always be taken into account when considering the diagnosis of primary versus secondary MN.

Absence of circulating anti-phospholipase A2 receptor autoantibodies does not rule out a diagnosis of primary MN.

CPT Code:
86255

Day(s) Performed: Monday, Wednesday, Friday **Report Available:** 3 to 7 days

Questions
Contact Nancy Benson, Laboratory Technologist Resource Coordinator at 800-533-1710.